Payment overview · 2025
General Payments
$285.85
13 reported records · 7 companies
Healthcare provider profile · identity verified
Stanley D Leffew, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PAMPA, TX · NPI 1932406980
Verified facts
What the public records show
CMS Open Payments records show Stanley D Leffew, FNP-C received $285.85 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $110.85 | 38.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.42 | 23.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.05 | 8.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $23.08 | 8.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.91 | 8.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.50 | 6.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.04 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $285.85 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $67.12 | 4 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $43.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 121 |
| Gabapentin | Gabapentin | 400 | 84 |
| Lisinopril | Lisinopril | 380 | 94 |
| Losartan Potassium | Losartan Potassium | 343 | 91 |
| Metformin Hcl | Metformin Hcl | 303 | 66 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 254 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 59 |
| Omeprazole | Omeprazole | 232 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 58 |
| Pregabalin | Pregabalin | 228 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 210 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 47 |
| Furosemide | Furosemide | 202 | 52 |
| Prednisone | Prednisone | 191 | 129 |
| Alprazolam | Alprazolam | 178 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 175 | 51 |
| Trazodone Hcl | Trazodone Hcl | 161 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 161 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 40 |
| Jardiance | Empagliflozin | 149 | 32 |
| Tramadol Hcl | Tramadol Hcl | 149 | 43 |
| Meloxicam | Meloxicam | 148 | 29 |
| Potassium Chloride | Potassium Chloride | 145 | 36 |
| Clonazepam | Clonazepam | 144 | 22 |
| Trulicity | Dulaglutide | 140 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 43 |
| Allopurinol | Allopurinol | 136 | 27 |
| Baclofen | Baclofen | 130 | 21 |
| Alendronate Sodium | Alendronate Sodium | 127 | 28 |
| Famotidine | Famotidine | 122 | 22 |
| Carvedilol | Carvedilol | 115 | 32 |
| Temazepam | Temazepam | 107 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 25 |
| Azithromycin | Azithromycin | 97 | 74 |
| Lorazepam | Lorazepam | 94 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 22 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Ozempic | Semaglutide | 89 | 19 |
| Promethazine Hcl | Promethazine Hcl | 79 | 26 |
| Celecoxib | Celecoxib | 77 | 19 |
| Eliquis | Apixaban | 75 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 19 |
| Xarelto | Rivaroxaban | 74 | 14 |
| Montelukast Sodium | Montelukast Sodium | 69 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 17 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Bupropion Xl | Bupropion Hcl | 61 | 13 |
| Propranolol Hcl | Propranolol Hcl | 60 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 18 |
| Diazepam | Diazepam | 57 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 11 |
| Etodolac | Etodolac | 57 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 38 |
| Ezetimibe | Ezetimibe | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 19 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 11 |
| Estradiol | Estradiol | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 11 |
| Glipizide | Glipizide | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 16 |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Atenolol | Atenolol | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 11 |
| Nitroglycerin | Nitroglycerin | 29 | 14 |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 20 |
| Butorphanol Tartrate | Butorphanol Tartrate | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 15 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $285.85 · 13 records | Abbott Laboratories | ABRE, Auvelity, ESPRIT, QULIPTA, REXULTI, TONMYA, UBRELVY, ULTREON, VRAYLAR, VYEPTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error